Trump’s ‘America First’ Vaccine Agenda May Leave Us Last

By using the usual patent monopoly framework rather than international open-source collaboration, the coronavirus vaccine may prove both elusive and more costly for Americans.

by

The American Prospect is fiercely independent and reader-funded. Your support directly funds our team of investigative reporters, fact-checkers, and editors who produce in-depth journalism that holds the powerful accountable.

If you believe in reporting that informs, challenges, and inspires, there are two key ways to support us:


Donate to keep our nonprofit newsroom strong and fearless
Subscribe to our award-winning print magazine and receive our hard-hitting reporting and analysis in your mailbox 6 times a year

Your support makes our journalism possible. Thank you for standing with us.